The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Knut and Alice Wallenberg Foundation allocates SEK 1.6 billion to life science with a focus on clinical research

Guld glitter

Knut and Alice Wallenberg Foundation is allocating additional funds to patient‑oriented, clinical research. The initiative will, among other things, strengthen research at the four Wallenberg Centres for Molecular Medicine located in Gothenburg, Lund, Linköping, and Umeå, as well as at Karolinska Institutet and Uppsala University.

We are thrilled to announce that the Knut and Alice Wallenberg Foundation (KAW) is investing in patient-oriented clinical research across Sweden. This initiative will strengthen the four Wallenberg Centres for Molecular Medicine in Gothenburg, Lund, Linköping and Umeå, as well as leading environments at Karolinska Institutet and Uppsala University.

As part of this initiative, support is included for around 80 Clinical Fellows – physicians who will have the opportunity to both work clinically and conduct research. It is a joint effort where the involved universities and the regions connected to the Wallenberg Centres for Molecular Medicine (WCMM), as well as Karolinska Institutet and Uppsala University, co‑finance the research portion of the physicians’ positions.

“This is a powerful, long-term initiative to ensure that Swedish clinical research does not lose momentum. There have been signs that fewer physicians are conducting research, which is why we are very pleased that, together with the universities and regions, we can now offer the conditions needed for more people to engage in research,” says Peter Wallenberg Jr.

WCMM Lund, have been awarded an additional SEK 155 million for 2027–2039This funding will enable us to recruit new clinical research leaders, further strengthen our translational research environment and continue to build on our strong foundation, in close collaboration with Region Skåne,” says Gunilla Westergren-Thorsson. We are very grateful for this opportunity and for the trust placed in WCMM Lund” 

This long-term support will help us continue advancing molecular medicine and improving patient outcomes, both regionally and nationally.